As trade tensions ease with new agreements and the Federal Reserve maintains its interest rate, the Canadian market is experiencing a period of cautious optimism. This backdrop creates a unique opportunity for investors to explore smaller or newer companies that might be overlooked in more stable times. While "penny stocks" may seem like an outdated term, they continue to represent potential value, especially when these companies are built on solid financial foundations and demonstrate promising growth potential.
Top 10 Penny Stocks In Canada
| Name | Share Price | Market Cap | Rewards & Risks |
| Westbridge Renewable Energy (TSXV:WEB) | CA$0.81 | CA$81.93M | ✅ 3 ⚠️ 3 View Analysis > |
| NTG Clarity Networks (TSXV:NCI) | CA$2.35 | CA$92.67M | ✅ 4 ⚠️ 2 View Analysis > |
| Silvercorp Metals (TSX:SVM) | CA$4.97 | CA$1.11B | ✅ 5 ⚠️ 2 View Analysis > |
| Orezone Gold (TSX:ORE) | CA$1.02 | CA$563.85M | ✅ 4 ⚠️ 2 View Analysis > |
| Mandalay Resources (TSX:MND) | CA$4.75 | CA$456.27M | ✅ 3 ⚠️ 2 View Analysis > |
| McChip Resources (TSXV:MCS) | CA$0.63 | CA$3.6M | ✅ 2 ⚠️ 5 View Analysis > |
| PetroTal (TSX:TAL) | CA$0.59 | CA$530.84M | ✅ 3 ⚠️ 3 View Analysis > |
| Pulse Seismic (TSX:PSD) | CA$2.53 | CA$129.43M | ✅ 1 ⚠️ 2 View Analysis > |
| Findev (TSXV:FDI) | CA$0.495 | CA$13.32M | ✅ 2 ⚠️ 3 View Analysis > |
| BluMetric Environmental (TSXV:BLM) | CA$1.33 | CA$53.26M | ✅ 2 ⚠️ 4 View Analysis > |
Click here to see the full list of 909 stocks from our TSX Penny Stocks screener.
Let's uncover some gems from our specialized screener.
Planet 13 Holdings (CNSX:PLTH)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Planet 13 Holdings Inc., along with its subsidiaries, cultivates and offers cannabis and cannabis-infused products for both medical and retail markets in the United States, with a market cap of CA$121.94 million.
Operations: The company generates revenue of $116.41 million from its cultivation, production, and distribution operations in the cannabis sector.
Market Cap: CA$121.94M
Planet 13 Holdings, with a market cap of CA$121.94 million and US$116.41 million in revenue, is expanding its footprint in Florida with new dispensaries in Edgewater, Orange Park, and Port Richey. Despite being unprofitable and having a negative return on equity of -42.41%, the company has more cash than debt and maintains a stable cash runway for over three years. Its management team is experienced with an average tenure of 4.1 years, though volatility remains high compared to other Canadian stocks. Shareholders have not faced significant dilution recently despite increasing losses over the past five years at 33.4% annually.
- Navigate through the intricacies of Planet 13 Holdings with our comprehensive balance sheet health report here.
- Examine Planet 13 Holdings' earnings growth report to understand how analysts expect it to perform.
MediPharm Labs (TSX:LABS)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: MediPharm Labs Corp. is a pharmaceutical company that specializes in producing and selling purified cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products across Canada, Australia, Germany, and internationally with a market cap of CA$39.44 million.
Operations: The company's revenue is primarily generated from the production and sale of cannabis extracts and derivative products, totaling CA$41.96 million.
Market Cap: CA$39.44M
MediPharm Labs, with a market cap of CA$39.44 million, has shown revenue growth, reporting CA$11.53 million in sales for Q1 2025 compared to CA$10.67 million the previous year. Despite being unprofitable with a negative return on equity of -24.76%, it has reduced its net loss from CA$3.61 million to CA$0.387 million year-over-year and improved its debt position significantly over five years. The company maintains more cash than total debt and has sufficient cash runway for over a year based on current free cash flow trends, although it faces challenges from investor activism regarding board nominations.
- Take a closer look at MediPharm Labs' potential here in our financial health report.
- Gain insights into MediPharm Labs' outlook and expected performance with our report on the company's earnings estimates.
California Nanotechnologies (TSXV:CNO)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: California Nanotechnologies Corp. focuses on the research, development, and production of nanocrystalline materials through grain size reduction, with a market cap of CA$26.63 million.
Operations: Currently, there are no reported revenue segments for California Nanotechnologies Corp.
Market Cap: CA$26.63M
California Nanotechnologies Corp., with a market cap of CA$26.63 million, is currently pre-revenue and unprofitable but shows potential in its strategic moves towards commercial production. Recent purchase orders from Oerlikon Metco and AbTech Industries, valued at US$115,000, highlight growing demand for its advanced materials services. The company has achieved ISO 9001 certification, enhancing its ability to secure larger contracts. While short-term liabilities exceed assets by $0.5M and share price volatility remains high, California Nanotechnologies benefits from being debt-free with a stable cash runway exceeding three years due to positive free cash flow growth.
- Unlock comprehensive insights into our analysis of California Nanotechnologies stock in this financial health report.
- Assess California Nanotechnologies' previous results with our detailed historical performance reports.
Turning Ideas Into Actions
- Reveal the 909 hidden gems among our TSX Penny Stocks screener with a single click here.
- Curious About Other Options? The latest GPUs need a type of rare earth metal called Dysprosium and there are only 24 companies in the world exploring or producing it. Find the list for free.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if MediPharm Labs might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com